Sandoz launches authorized Beyaz generic

PRINCETON, N.J. — Sandoz on Thursday announced the U.S. launch of its authorized generic of Bayer’s contraceptive Beyaz (drospirenone 3 mg/ethinyl estradiol 0.02 mg/ levomefolate calcium tablets 0.451 mg and levomefolate calcium tablets 0.451 mg). 

 

Beyaz had U.S. sales of about $134 million for the 12 months ended August 2016, according to IMS Health data. The drug comes with a boxed warning about serious cardiovascular events, the risk of which is increased from the use of combination oral contraceptives. It also warns that women older than 35 years in age who smoke should not use the drug.